Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy-Reference-Cited by-同舟云学术

Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy

Published:2017-07-28 Issue:9 Volume:37 Page:807-817
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Maharshi Vikas^ORCID,Hasan Shazia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-017-0557-5/fulltext.html

Reference23 articles.

1. Shababi M, Lorson CL, Rudnik-Schoneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J. Anat. 2014;224:15–28.

2. d’Ydewalle Constantin, Sumner Charlotte J. Spinal muscular atrophy therapeutics: where do we stand? Neurotherapeutics. 2015;12:303–16.

3. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157–67.

4. Hoy SM. Nusinersen: first global approval. Drugs. 2017. doi: 10.1007/s40265-017-0711-7 .

5. Sullivan DL. Spinraza spinal muscular atrophy. Washington state health care authority. 2017. https://www.hca.wa.gov/assets/program/dur-spinraza-2017-2-22.pdf . Accessed 31 Mar 2017.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world pharmacovigilance study of nusinersen based on the FAERS database;2024-06-13

2. Evaluating the performance of four assays for carrier screening of spinal muscular atrophy;Clinica Chimica Acta;2023-08

3. Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease;Frontiers in Physiology;2022-01-28

4. Gene Therapy;Comprehensive Pharmacology;2022

5. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs;Neuromuscular Disorders;2021-04